Values as of: 2024-11-13
COMMON STOCK | Biotechnology |
Last Closing
USD 215.68Change
-16.25 (-7.01)%Market Cap
USD 14.18BVolume
300.00Analyst Target
N/AVerdict
Verdict
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Company Website : https://www.genmab.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| UCBJY | UCB SA ADR |
+0.03 (+0.03%) |
USD 37.20B |
| UCBJF | UCB SA |
N/A |
USD 36.42B |
| ARGNF | argenx SE |
N/A |
USD 35.17B |
| WXIBF | WuXi Biologics |
N/A |
USD 9.23B |
| IVBIY | IVBIY |
N/A |
USD 8.96B |
| ZLDPF | Zealand Pharma A/S |
-4.12 (-3.43%) |
USD 8.69B |
| WXXWY | WuXi Biologics (Cayman) Inc |
-0.14 (-3.37%) |
USD 8.62B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 8.61B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 8.43B |
| AKESF | Akeso, Inc. |
+0.35 (+4.02%) |
USD 8.00B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -31.68% | 40% | F | 29% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.68% | 40% | F | 30% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -33.45% | 39% | F | 29% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -33.45% | 39% | F | 29% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -1.06% | 69% | C- | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -1.06% | 69% | C- | 62% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 4.80% | 49% | F | 46% | F | ||
| Dividend Return | 4.80% | 49% | F | 42% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 32.79% | 86% | B+ | 69% | C- | ||
| Risk Adjusted Return | 14.65% | 63% | D | 47% | F | ||
| Market Capitalization | 14.18B | 99% | N/A | 93% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
